Tolvaptan – Hyponatriämie bei SIADH gezielt behandeln

• Literatur

• 1 Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med 2006; 119 (Suppl. 01) S30-S35
• 2 Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007; 356: 2064-2072
• 3 Gill G, Huda B, Boyd A et al. Characteristics and mortality of severe hyponatraemia--a hospital-based study. Clin Endocrinol (Oxf) 2006; 65: 246-249
• 4 Callahan MA, Do HT, Caplan DW, Yoon-Flannery K. Economic impact of hyponatremia in hospitalized patients: a retrospective cohort study. Postgrad Med 2009; 121: 186-191
• 5 Adrogué HJ. Consequences of inadequate management of hyponatremia. Am J Nephrol 2005; 25: 240-249
• 6 Renneboog B, Musch W, Vandemergel X et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006; 119: 71.e1-78
• 7 Schrier RW, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V₂-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112